Contrary to the positive effects on the surrogate markers of NAFLD, a 12-week treatment of patients with diagnosed hypertriglyceridemia and an MRI-PDFF above 5.5% showed no influence on the ALT level and a slight increase in the AST level compared to the placebo group. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.